A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant Candidates

Desensitization protocols comprising plasmapheresis, IVIGs, and rituximab and/or bortezomib have allowed for successful kidney transplantation in some highly HLA-sensitized patients with end-stage renal disease. However, the optimal combination of these therapies and their proper timing remains enti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ide, Kentaro, Tanaka, Yuka, Sasaki, Yu, Tahara, Hiroyuki, Ohira, Masahiro, Ishiyama, Kohei, Tashiro, Hirotaka, Ohdan, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Original Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946466/
https://www.ncbi.nlm.nih.gov/pubmed/27500219
http://dx.doi.org/10.1097/TXD.0000000000000526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946466/
https://www.ncbi.nlm.nih.gov/pubmed/27500219
http://dx.doi.org/10.1097/TXD.0000000000000526

Ejemplares similares